Featured in our #CapitalRegion newsletter: Ascentage prices first biotech IPO of 2025, raising $126M

The China-based drug developer has benefited from an upswing in licensing deals for experimental medicines that originated in the country’s laboratories.

More:#lifescience #biotech #healthcare #IPO